Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000669565 | SCV000794330 | uncertain significance | Deficiency of galactokinase | 2017-11-08 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000669565 | SCV004197944 | likely pathogenic | Deficiency of galactokinase | 2023-04-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000669565 | SCV004297549 | likely pathogenic | Deficiency of galactokinase | 2023-06-23 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 174 of the GALK1 protein (p.Glu174Lys). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALK1 protein function. ClinVar contains an entry for this variant (Variation ID: 554016). This missense change has been observed in individual(s) with galactokinase deficiency (PMID: 28173647). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is present in population databases (no rsID available, gnomAD 0.04%). |
Fulgent Genetics, |
RCV000669565 | SCV005651911 | likely pathogenic | Deficiency of galactokinase | 2024-06-12 | criteria provided, single submitter | clinical testing |